The research team, led by Jaeun Ahn and Joshua M. Sill of Eastern Virginia Medical School at Old Dominion University, together with colleagues at Jacobi Medical Center and National Cheng Kung University Hospital, drew on the TriNetX Global Collaborative Network, a federated health research platform aggregating de-identified records from more than 160 million patients across over 120 healthcare organizations worldwide. From this vast dataset, the investigators identified adults diagnosed with obstructive sleep apnea between January 2010 and November 2021 who had a body mass index above 30. Crucially, they excluded anyone with pre-existing heart failure, pulmonary hypertension, or myocardial infarction, ensuring that the outcomes they tracked were genuinely new events rather than complications of established disease.

The study design followed the conventions of a retrospective propensity score-matched cohort analysis. Patients prescribed a GLP-1 receptor agonist, specifically semaglutide, liraglutide, or dulaglutide, within one year of their sleep apnea diagnosis formed the exposed cohort, numbering 18,774 individuals. The comparison group comprised 847,137 patients with sleep apnea and obesity who were never prescribed any GLP-1 receptor agonist before or after diagnosis. Because the two groups differed substantially at baseline, with drug users tending to be heavier, more often female, and more likely to have elevated hemoglobin A1c, the researchers applied greedy nearest-neighbor propensity score matching to balance the cohorts on demographics, comorbidities, medications, BMI, and glycemic control. After matching, 18,523 patients remained in each arm, well balanced on every measured characteristic, including a mean age of roughly 55 years and a mean BMI near 40.8 in both groups.

Over a three-year follow-up period analyzed with Cox proportional hazards models, the differences between the groups were striking. New-onset heart failure, the primary outcome, occurred in 1,416 patients in the GLP-1 receptor agonist cohort versus 1,791 in the matched comparison group, corresponding to a 24 percent reduction in risk (hazard ratio 0.76, 95 percent confidence interval 0.71 to 0.82). Pulmonary hypertension showed an even larger relative reduction of 33 percent (hazard ratio 0.67). Acute myocardial infarction was likewise less frequent among drug users, with a hazard ratio of 0.76. Most dramatic of all was all-cause mortality: 550 deaths in the treated group against 945 in the untreated group, a 43 percent lower risk of dying from any cause (hazard ratio 0.57, 95 percent confidence interval 0.51 to 0.63). Ischemic stroke also trended lower, reaching statistical significance with a hazard ratio of 0.90.

Timing mattered as much as magnitude. Kaplan-Meier survival curves for heart failure, myocardial infarction, and death showed early separation between the two cohorts, a pattern the authors interpret as suggestive of direct cardiovascular benefits that extend beyond the slow, gradual effects of weight loss alone. If the drugs were working purely by shedding pounds, one might expect the curves to diverge only after substantial weight reduction had accumulated over many months. The early divergence instead hints at mechanisms acting more rapidly, such as improvements in endothelial function, reductions in systemic inflammation, and favorable hemodynamic changes. The pulmonary hypertension curve, by contrast, separated later, which is consistent with a benefit mediated more by sustained metabolic and weight-related improvements.

An exploratory subgroup analysis added an important layer of robustness. Each individual agent within the class was independently associated with lower heart failure risk: liraglutide with a hazard ratio of 0.73, dulaglutide with 0.75, and semaglutide with 0.83. The consistency across three chemically distinct molecules that share a common mechanism strengthens the biological plausibility of a class effect rather than an artifact tied to one particular drug. Most patients in the cohort received liraglutide (51.7 percent), followed by dulaglutide (35.0 percent) and semaglutide (19.1 percent), reflecting prescribing patterns during the study window, which predated the widespread adoption of higher-dose semaglutide formulations for weight management.

The findings arrive against a backdrop of rapidly evolving evidence on incretin-based therapies and sleep apnea. In the randomized SURMOUNT-OSA trial, tirzepatide, a dual agonist of the GLP-1 and GIP receptors, improved the apnea-hypopnea index, lowered high-sensitivity C-reactive protein, and reduced systolic blood pressure, pointing to multifaceted cardiometabolic effects. Recent meta-analyses have confirmed that GLP-1 receptor agonists and tirzepatide both significantly reduce the severity of sleep apnea. What has been missing, the authors argue, is direct evidence on hard cardiovascular endpoints, particularly incident heart failure, in patients with sleep apnea. This study addresses that gap using observational data, and its results align with the cardiovascular benefit profile these drugs established in large randomized trials among patients with type 2 diabetes, including SUSTAIN-6 for semaglutide, LEADER for liraglutide, and REWIND for dulaglutide.

The clinical context makes the results especially consequential. Positive airway pressure therapy remains the cornerstone of sleep apnea treatment, and prior research has explored its cardiovascular effects, though often in small samples; one frequently cited proof-of-concept study by O’Donnell and colleagues included only 30 participants. Many patients with obesity struggle to adhere to mask-based therapy, leaving a substantial residual risk population. If GLP-1 receptor agonists can serve as an adjunctive or alternative strategy, they could offer cardiovascular protection to patients who cannot or will not tolerate airway pressure devices, while simultaneously improving sleep-disordered breathing itself. The prospect of a single pharmacological intervention addressing obesity, apnea severity, and cardiovascular risk simultaneously is precisely what has made this drug class the focus of such intense scientific and public attention.

Yet the authors are careful to frame the findings as hypothesis-generating rather than definitive. The retrospective observational design precludes causal inference, and several clinically important variables were unavailable in the TriNetX database. The severity of sleep apnea, measured by the apnea-hypopnea index, was not captured, nor was adherence to positive airway pressure therapy, longitudinal weight trajectories, or the duration of diabetes. More severe apnea might independently prompt both higher cardiovascular risk and more aggressive treatment, and differential weight loss between the cohorts, expected given the drugs’ known effects, may have contributed to the outcome differences. Lifestyle factors such as alcohol consumption and exercise frequency were also unmeasured, leaving open the possibility of residual confounding. Reliance on administrative ICD-10 diagnosis codes introduces the potential for misclassification, although the authors note that such errors are likely nondifferential and would tend to bias the results toward the null, making the observed associations conservative estimates.

The researchers conclude that prospective studies are needed to validate the findings, ideally randomized controlled trials specifically evaluating the cardiovascular impact of GLP-1 receptor agonists in patients with obstructive sleep apnea and obesity, incorporating serial assessments of apnea severity, airway pressure therapy adherence, and body weight trajectories. Until such trials are completed, the study stands as one of the largest real-world examinations of these drugs in a sleep apnea population, and its message is hard to ignore: among more than 37,000 carefully matched patients, those taking GLP-1 receptor agonists were markedly less likely to develop heart failure, pulmonary hypertension, or heart attack, and markedly less likely to die. As prescriptions of these agents continue to climb worldwide, the question of whether they should be considered cardiovascular risk modifiers for the millions of obese patients with sleep apnea has moved from speculation toward the center of clinical debate.

Subject of Research: Cardiovascular effects of GLP-1 receptor agonists in obese patients with obstructive sleep apnea

Article Title: Glucagon-like peptide receptor agonists (GLP-1RAs) as cardiovascular risk modifiers in obstructive sleep apnea and obesity: a real-world study

Article References: Ahn, J., Song, J., Admire, K., Chang, Y., Chi, K.-Y., Gordon, N. T., & Sill, J. M. (2026). Glucagon-like peptide receptor agonists (GLP-1RAs) as cardiovascular risk modifiers in obstructive sleep apnea and obesity: a real-world study. Journal of Clinical Sleep Medicine, 22(1), Article 102. https://doi.org/10.1007/s44470-026-00110-x

Image Credits: AI Generated

DOI: 10.1007/s44470-026-00110-x

Keywords: obstructive sleep apnea, GLP-1 receptor agonists, obesity, heart failure, pulmonary hypertension, cardiovascular risk, semaglutide, liraglutide, dulaglutide, propensity score matching, TriNetX, real-world evidence

The stakes of this comparison are enormous. Type 2 diabetes now affects an estimated 589 million adults worldwide as of 2024, a figure projected to climb to 853 million by 2050. Because the disease drives complications through both chronic hyperglycemia and the twin burdens of obesity and cardiovascular disease, contemporary treatment guidelines no longer ask simply whether a drug lowers glucose. They demand sustained reductions in hemoglobin A1c, meaningful weight reduction, cardiovascular safety, and tolerability that patients can live with for decades. Both tirzepatide and dulaglutide are once-weekly subcutaneous injections, but they work differently at the molecular level, and until now no trial had ever compared all clinically relevant doses of the two drugs simultaneously.

Dulaglutide is a selective glucagon-like peptide-1 receptor agonist, a class of drugs that mimics an intestinal hormone to boost glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite. It carries hard cardiovascular outcome evidence: in the landmark REWIND trial, dulaglutide reduced major adverse cardiovascular events compared with placebo in people with type 2 diabetes. Tirzepatide, by contrast, is a first-in-class dual agonist that engages both the GIP and GLP-1 receptors, amplifying the incretin effect through two complementary hormonal pathways. Head-to-head trials had already hinted that tirzepatide’s dual mechanism translated into greater reductions in HbA1c and body weight, but individual studies compared only selected dose pairs, leaving clinicians without a comprehensive map of which specific dose delivers which specific benefit.

The research team, following Cochrane Handbook methodology and PRISMA reporting guidelines with a prospectively registered protocol, searched four major databases through the end of 2025 and identified four eligible randomized trials. Three of these were judged to carry low risk of bias across all assessed domains; the fourth, an open-label switching study, raised some concerns because participants and clinicians knew which treatment was being given. The largest trial by far was the SURPASS-CVOT cardiovascular outcomes study, which enrolled 13,165 patients with established atherosclerotic cardiovascular disease and demonstrated that tirzepatide titrated up to 15 milligrams was noninferior to dulaglutide 1.5 milligrams for the composite of cardiovascular death, myocardial infarction, or stroke over a median follow-up of roughly four years.

Using a frequentist random-effects network model, the analysts computed treatment effects and SUCRA rankings, a statistical measure of each dose’s cumulative probability of being among the most effective options. The results formed a clean dose-response gradient. For glycemic control, tirzepatide 15 milligrams ranked highest at both 12 and 24 weeks, achieving SUCRA values of 0.95 and 0.99 respectively, while dulaglutide 1.5 milligrams sat near the bottom of the efficacy rankings. At 24 weeks, tirzepatide 15 milligrams reduced HbA1c significantly more than tirzepatide 5 milligrams, and both dulaglutide 0.75 and 1.5 milligrams were associated with meaningfully smaller reductions. The differences of 0.2 to 0.4 percentage points between higher and lower tirzepatide doses are clinically meaningful, because shifts of that magnitude can move patients across standard treatment targets and delay the need for therapy intensification.

The weight findings followed the same pattern with even sharper separation. By week 16, tirzepatide 15 milligrams outperformed tirzepatide 5 milligrams by an additional 2.68 kilograms of weight loss, and the contrast against the weakest doses was dramatic: dulaglutide 0.75 milligrams and tirzepatide 1 milligram trailed the top dose by roughly 5 to 8 kilograms. Tirzepatide 15 milligrams earned a SUCRA of 0.95 for weight reduction, with the 10 milligram dose close behind, while tirzepatide 1 milligram ranked nearly last. Notably, the early weight outcomes showed substantial statistical heterogeneity, which the authors attribute to the sensitivity of short-term weight trajectories to titration schedules, baseline body mass index, diabetes duration, and transient gastrointestinal symptoms that can temporarily suppress food intake during dose escalation.

Safety told the mirror-image story. Tirzepatide 1 milligram carried the lowest risk of any treatment-emergent adverse event and of nausea, while dulaglutide 0.75 milligrams showed the lowest risks of diarrhea and vomiting. At the other end of the spectrum, both tirzepatide 15 milligrams and dulaglutide 1.5 milligrams were associated with significantly higher nausea risk compared with tirzepatide 5 milligrams. This gradient is biologically coherent: higher incretin receptor engagement intensifies slowed gastric emptying and central satiety signaling, which are precisely the mechanisms that drive both the metabolic benefits and the gastrointestinal complaints. Encouragingly, no significant differences emerged between any dose pairs for all-cause death, severe hypoglycemia, serious adverse events, pancreatitis, treatment discontinuation, or the composite cardiovascular endpoint, although the authors caution that wide confidence intervals for these rare outcomes mean the absence of statistical differences cannot be read as proof of equivalent safety.

The team stress-tested their findings with a battery of sensitivity analyses, including one that removed the dominant SURPASS-CVOT trial entirely to check whether its enormous statistical weight was distorting the network. The core conclusions held. Some outcomes, notably HbA1c at 12 weeks, early body weight change, and nausea and vomiting, proved sensitive to the inclusion of the Japanese SURPASS J-mono trial, which compared tirzepatide against the 0.75 milligram dulaglutide dose approved in Japan rather than the 1.5 milligram standard used elsewhere. Inconsistency testing using both design-by-treatment interaction models and node-splitting found no meaningful disagreement between direct and indirect evidence for most outcomes, lending credibility to the network’s internal structure.

The clinical implications are refreshingly practical. For patients whose primary goals are maximal HbA1c reduction and weight loss, the data support escalating to tirzepatide 10 or 15 milligrams when tolerability permits, with an expected stepwise advantage over lower doses and over any dulaglutide regimen. For patients whose priority is gastrointestinal tolerability, starting at lower doses such as dulaglutide 0.75 milligrams or tirzepatide 1 milligram remains a reasonable strategy, accepting more modest metabolic gains and possible later intensification. The findings also reinforce the results of the SURPASS-SWITCH trial, which showed that patients inadequately controlled on submaximal dulaglutide achieved greater HbA1c and weight improvements by switching to tirzepatide than by pushing the dulaglutide dose higher. An important interpretive caveat applies to the early time points: many participants assigned to the highest tirzepatide doses were still in protocol-mandated dose escalation at weeks 12 and 16, meaning the full maintenance-dose effects may be even larger than these figures suggest.

The authors are candid about the limitations. Only four trials informed the network, several dose nodes rested on sparse comparisons, and long-term durability, late adverse events, and sustained discontinuation could not be assessed because later time points were not consistently reported across trials. Some data were digitized from published figures, introducing the possibility of minor extraction error despite independent double-checking. Still, within those constraints, the analysis delivers something no single trial could: a unified, dose-level ranking of the two most widely used once-weekly injectable therapies for type 2 diabetes. The message for the millions of patients and their clinicians navigating this decision is one of individualized titration, balancing the escalating metabolic rewards of higher tirzepatide doses against the dose-related gastrointestinal costs, with the reassurance that cardiovascular safety appears preserved across the spectrum.

Subject of Research: Comparative efficacy and safety of tirzepatide versus dulaglutide doses in type 2 diabetes

Article Title: Efficacy and Safety of Tirzepatide Versus Dulaglutide in Type 2 Diabetes With or Without Established Atherosclerotic Cardiovascular Disease: A Network Meta‐Analysis of Randomized Clinical Trials

Article References: Hageen, A. W., Gadelmawla, A. F., Saleh, A. O., Bahnasy, S., Eladawi, S., Abdelaziz, M., Iyad, K., Kandil, A. H., Zinhom, K., Mohamed, M. R., Abdulhay, H., Turkman, M., Abdelazeem, B., & Fonarow, G. C. (2026). Efficacy and Safety of Tirzepatide Versus Dulaglutide in Type 2 Diabetes With or Without Established Atherosclerotic Cardiovascular Disease: A Network Meta‐Analysis of Randomized Clinical Trials. Endocrinology, Diabetes & Metabolism, 9(5), Article e70313. https://doi.org/10.1002/edm2.70313

Image Credits: AI Generated

DOI: 10.1002/edm2.70313

Keywords: tirzepatide, dulaglutide, type 2 diabetes, network meta-analysis, HbA1c, weight loss, GLP-1 receptor agonist, GIP, cardiovascular outcomes, gastrointestinal adverse events, dose-response, incretin therapy

The research team, led by Katie D. Stewart and Louis S. Matza of PPD Evidera Patient-Centered Research at Thermo Fisher Scientific, together with colleagues at Eli Lilly and Company, conducted semi-structured exit interviews after participants had fully completed the multiyear SURPASS-CVOT trial. That phase 3, randomized, double-blind, noninferiority study compared tirzepatide, a dual agonist of the GLP-1 and GIP receptors, with dulaglutide, a pure GLP-1 receptor agonist, in patients with type 2 diabetes and atherosclerotic cardiovascular disease. Because treatment assignment remained blinded until the interviews and analyses were finished, participants spoke about their experience without knowing which drug they had received, and the researchers deliberately presented results for the combined sample.

Recruitment took place across ten US trial sites in California, Florida, Illinois, Kansas, Maryland, and Texas. Of 147 people invited, 74 completed interviews between August and October 2025, each lasting roughly 90 minutes by telephone or web conference. The participants were predominantly male at 63.5 percent, with a mean age of 68.9 years, and had lived with type 2 diabetes for an average of 18.6 years. Most carried substantial cardiovascular histories: nearly 80 percent reported a prior heart attack or heart disease, and hypertension and arthritis were each present in roughly 45 percent of the sample. On average, they had received the blinded study medication for 45.0 months, and during that time their weight fell by a mean of 14.6 kilograms while HbA1c dropped 1.7 percentage points, from 8.3 percent to 6.6 percent.

The interview methodology was rigorous by qualitative standards. Six trained female interviewers used a guide that began with open-ended questions about changes participants noticed, then probed systematically for specific concepts such as weight, blood sugar, energy, appetite, sleep, and joint pain. Transcripts were coded in ATLAS.ti by seven trained coders who achieved greater than 90 percent agreement before coding independently, and the team formally documented saturation: fewer than 5 percent of concepts first appeared in the final 21 interviews, and no new concepts emerged in the last 11. That statistical-style discipline matters, because it signals that the 74 voices captured here likely represent the full range of experiences among long-term users of these drugs.

The headline finding is the sheer breadth and consistency of perceived benefit. Ninety-nine percent of participants reported at least one treatment benefit, and 97.3 percent described improved glycemic control, most often citing lower HbA1c but also steadier day-to-day blood glucose. Weight reduction was reported by 91.9 percent, with 20 participants characterizing the loss as substantial using words like dramatic or drastic, and most noticing the change within the first six months. Reduced appetite was described by 78.4 percent, frequently as a curbed or suppressed drive to eat and a new sense of fullness after smaller portions. Nearly two-thirds reported improved diet and eating habits, and 41.9 percent said their desire for unhealthy food had diminished. More than half reported increased energy, and a striking number volunteered improvements in conditions beyond diabetes, including joint pain or osteoarthritis in 18.9 percent and sleep apnea in 8.1 percent.

Those physical changes translated into lived consequences. Eighty-five percent of participants said the treatment affected their quality of life, with 81 percent describing that impact as positive, and 77 percent reported changes in at least one domain of daily activity, most commonly physical activities, followed by activities of daily living, family activities, social life, leisure, and work. Seventy percent said the treatment changed their interactions with others, often through comments on their appearance or weight loss. Thirty-nine percent reported emotional effects, most frequently feeling happier, more confident, more motivated, or less worried, and these were usually tied to the weight loss or steadier glucose. Even health behaviors shifted: among participants who drank alcohol, ten reported drinking less or wanting it less, and four of thirteen nicotine users reported smoking less or quitting altogether.

The safety picture was familiar but not trivial. Fifty-four participants reported at least one adverse event, with gastrointestinal symptoms dominating: nausea was the most common at 28.4 percent, followed by diarrhea, stomach upset, vomiting, constipation, and reflux. Six participants experienced low blood sugar episodes, and four described appetite suppression so severe that food became repulsive, with one tirzepatide-treated participant recalling that seeing food made him sick and he knew he was really sick because he always loved to eat. Two participants lost more weight than they wanted, and one 86-year-old man reduced his own dose after deciding the weight loss had gone too far. Other reported events included fatigue, insomnia, body soreness, muscle loss, injection-site reactions, and chills. Yet despite these burdens, 93 percent said they would be very likely or likely to continue the medication if it were available, and 93 percent would recommend it to others.

An exploratory subgroup analysis hinted at differences between the two drugs, though the study was never designed to compare them statistically. Benefits trended somewhat more frequently among the 43 tirzepatide-treated participants than the 31 on dulaglutide: improved glycemic control was reported by 100 percent versus 94 percent, weight reduction by 95 percent versus 87 percent, reduced appetite by 86 percent versus 68 percent, improved eating habits by 74 percent versus 52 percent, and increased energy by 67 percent versus 42 percent. Similar patterns appeared for quality-of-life impacts, including comments from other people, which 67 percent of tirzepatide patients reported versus 32 percent of dulaglutide patients. Whether these gaps reflect true pharmacological differences, the dual GIP activity of tirzepatide, or simply sample composition remains an open question for larger dedicated comparisons.

What distinguishes this study from its predecessors is duration. Previous qualitative investigations of GLP-1-based therapies, including exit interviews from tirzepatide trials in diabetes, weight management, and obstructive sleep apnea, and a study of the triple agonist retatrutide, covered treatment periods of one year or less. Here, patients averaged 45 months on therapy, and their enthusiasm did not fade with time. The authors argue this is the first qualitative study to assess patient perceptions of GLP-1 receptor agonist-based treatment over multiple years, and the persistence of reported benefits suggests that the improvements patients describe in shorter trials are not a honeymoon effect but a durable feature of long-term treatment.

The authors are careful about the limits of their data. All participants had type 2 diabetes with elevated cardiovascular risk, so generalizability to broader diabetes populations is uncertain, and only US sites were interviewed despite the multinational trial. Selection bias may favor healthier or more satisfied patients, and only five of the 74 had discontinued treatment early, so the perspectives of people who quit these drugs are largely missing. Recall bias is also a concern, since interviews occurred an average of 6.1 months after the last dose because they were delayed until the trial database was locked. Most importantly, the researchers caution that improvements in sleep, osteoarthritis, cardiovascular health, alcohol use, and nicotine use may be secondary consequences of weight loss rather than direct drug effects, and the small numbers reporting them warrant caution. Still, the core message stands: when patients who lived with these medications for years are asked what mattered, they describe transformations in blood sugar, body weight, appetite, energy, and daily life that the trial’s quantitative endpoints could only partially capture, and nearly all of them would choose the treatment again.

Subject of Research: Patient-reported experiences of long-term treatment with tirzepatide and dulaglutide in adults with type 2 diabetes and atherosclerotic cardiovascular disease, assessed through qualitative exit interviews after the SURPASS-CVOT trial.

Article Title: Exit Interviews Examining Patient Experiences with Tirzepatide and Dulaglutide for Treatment of Type 2 Diabetes in the SURPASS-CVOT Trial

Article References: Stewart, K. D., Matza, L. S., Chinthammit, C., Pavo, I., Bartee, A. K., & Boye, K. S. (2026). Exit Interviews Examining Patient Experiences with Tirzepatide and Dulaglutide for Treatment of Type 2 Diabetes in the SURPASS-CVOT Trial. Diabetes Therapy. https://doi.org/10.1007/s13300-026-01907-y

Image Credits: AI Generated

DOI: 10.1007/s13300-026-01907-y

Keywords: tirzepatide, dulaglutide, type 2 diabetes, GLP-1 receptor agonist, SURPASS-CVOT, exit interviews, qualitative research, patient-reported outcomes, weight loss, glycemic control, quality of life, cardiovascular disease